Disclaimer

This document is not for release, publication or distribution (in whole or in part), directly or indirectly and does not constitute an offer of securities for sale, in, into or from the United States (including its territories and possessions, any state of the United States and the District of Columbia), Australia, Canada, Japan or any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction. Any securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration under the Securities Act or an available exemption from, or transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable securities laws of any state or other jurisdiction of the United States. There will be no public offer of the securities of Informa plc (the "Company") in the United States.

This document is being provided to you solely for your information. This document and the related presentation do not constitute or form part of, and should not be construed as, any offer, invitation or recommendation to purchase, sell or subscribe for any securities in any jurisdiction and neither the issue of the information nor anything contained herein shall form the basis of or be relied upon in connection with, or act as an inducement to enter into, any investment activity.

The information and opinions contained in this document are provided as at the date of such presentation and are subject to change without notice. The information set out herein is subject to updating, completion, revision, verification and amendment, and such information may change materially. This document and the related presentation have not been independently verified, some of the information is subject to change, and no representation or warranty, express or implied, is made or given by or on behalf of the Company or any of their respective parent or subsidiary undertakings, or the subsidiary undertakings of any such parent undertakings, or any of such person's respective directors, officers, employees, agents, affiliates or advisers, as to, and no reliance should be placed on, the accuracy, completeness or fairness of the information or opinions contained in this document or the related presentation and no responsibility or liability is assumed by any such persons for any such information or opinions or for any errors or omissions. All information presented or contained in this document and the related presentation is provided as at the date of such presentation and is subject to verification, correction, completion and change without notice. In giving this presentation, none of the Company or any of its parent or subsidiary undertakings, or the subsidiary undertakings of any such parent undertakings, or any of such person's respective directors, officers, employees, agents, affiliates or advisers, undertakes any obligation to amend, correct or update this presentation or to provide the recipient with access to any additional information that may arise in connection with it.

Certain information contained herein constitutes "forward-looking statements", which can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue," "target" or "believe" (or the negatives thereof) or other variations thereon or comparable terminology. Due to various risks and uncertainties, including those which relate to the macroeconomic and global impact of COVID-19, actual events or results or actual performance of the Company may differ materially from those reflected or contemplated in such forward-looking statements. As a result, you should not rely on such forward-looking statements in making your investment decision. No representation or warranty (express or implied) is made as to the achievement or reasonableness of and no representation or warranty, express or implied, is made or given by or on behalf of the Company or any of their respective parent or subsidiary undertakings, or the subsidiary undertakings of any such parent undertakings, or any of such person's respective directors, officers, employees, agents, affiliates or advisers, as to, and no reliance should be placed on, the accuracy, completeness or fairness of the information or opinions contained in this document or the related presentation and no responsibility or liability is assumed by any such persons for any such information or opinions or for any errors or omissions. All information presented or contained in this document and the related presentation is provided as at the date of such presentation and is subject to verification, correction, completion and change without notice. In giving this presentation, none of the Company or any of its parent or subsidiary undertakings, or the subsidiary undertakings of any such parent undertakings, or any of such person's respective directors, officers, employees, agents, affiliates or advisers, undertakes any obligation to amend, correct or update this presentation or to provide the recipient with access to any additional information that may arise in connection with it.

Certain information contained herein constitutes "forward-looking statements", which can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue," "target" or "believe" (or the negatives thereof) or other variations thereon or comparable terminology. Due to various risks and uncertainties, including those which relate to the macroeconomic and global impact of COVID-19, actual events or results or actual performance of the Company may differ materially from those reflected or contemplated in such forward-looking statements. As a result, you should not rely on such forward-looking statements in making your investment decision. No representation or warranty (express or implied) is made as to the achievement or reasonableness of and no representation or warranty, express or implied, is made regarding future performance. The Company expressly disclaims any obligation or undertaking to release any updates or revisions to these forward-looking statements to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any statement is based after the date of this presentation or to update or to keep current any other information contained in this presentation.

Certain information contained herein is based on management estimates and the Company's own internal research. Management estimates have been made in good faith and represent the current beliefs of applicable members of the Company's management. While those management members believe that such estimates and research are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are subject to change without notice, and, by their nature, estimates may not be correct or complete. Accordingly, no representation or warranty (express or implied) is given that such estimates are correct or complete.

By reading or accepting a copy of this document, you agree to be bound by the foregoing limitations.
STABILITY & STRENGTH TO THE OTHER SIDE OF THE COVID-19 GLOBAL PANDEMIC

COVID-19 Market Disruption
- Temporary control measures
- Temporary travel restrictions
- Temporary restrictions on gatherings
- Temporary lockdown in US, UK and elsewhere
- Temporary deferral of Events revenues

COVID-19 Informa Action Plan
- Attractive, growing information markets
- International reach & balance (China/US)
- Portfolio of market-leading Brands
- No 1 B2B Trade Show Group globally
- High quality, recurring digital subscriptions revenues (Advanced Learning/Pharma & Finance)
- Highly cash generative

Informa: Stability & Strength

1Headroom calculation assumes c£640m headroom in RCF, £750m Surplus Credit Facility and a £1bn placing
2019 Full Year Results on 10 March

Six Consecutive Years of Growth

Fast & Targeted Response to COVID-19, with early 2020 impacts

Continued Growth & Delivery in 2019

- Strong revenue growth: +22% reported and +3.5% underlying
- Improved Adjusted Operating Profit growth: +28% reported and +6.5% underlying
- Increased Adjusted Diluted Earnings Per Share: +4.3% or +16.1% pro-forma
- Strong Free Cash Flow: £722m versus £503m in 2018
- Strengthened Balance Sheet: Reduction in leverage to 2.5x
- Enhanced Dividends Per Share: Proposed Final DPS +7.4%, delivering total 2019 DPS of 23.5p

Informa Response to COVID-19

COVID-19 ACTION PLAN

- Prioritize well-being of Colleagues, Customers & Markets
- Follow Government and health authority guidance and advice

Colleagues:
- Weekly COVID Executive Management Meeting
- In-market support, communications, guidance
- Proactive cost and cash management measures

Customer & Communities:
- Manage Brands and Businesses for long-term endurance and value
- Postponement Programme: Re-Schedule, Localise, Virtualise and Re-Phase (Berlin/AV CENTRE)
- Stay Connected: Virtualisation, digital partnering, online connections, virtual events, specialist content

LEADERSHIP TEAM FOCUSED ON LONG-TERM MARKET, BRAND & CUSTOMER VALUE
The COVID-19 Pandemic

**COVID-19 Market Realities**
- Scale and breadth of COVID-19 pandemic more far reaching than initially thought
- Government Control measures in more countries & locations
- Widespread restrictions on international and domestic travel
- Tighter control measures enforced, including temporary bans on all small and large gatherings
- Lockdown status in multiple regions, including in the US (c.45% of revenue) and UK (c.30% of Informa population)

**Gradual & Phased Return in China**
- Phased Return: COVID-19 Emergency Response Levels and control measures being eased gradually
- Region by Region: Pace of exit varies by region, including in relation to Events approvals
- Domestic v International: Initial focus on domestic audiences, with longer lead time to return of international buyer communities
- Revenue Attrition: Assumed level of attrition on returning brands (30-40%) due to macro-economic impact on customers
- Biosecurity: Working with partners to provide certified levels of biosecurity, enhanced hygiene, density management etc

**SCALE & REACH OF COVID-19 PANDEMIC MORE FAR REACHING THAN INITIALLY EXPECTED**
Q1 2020 Trading Update: Steady Performance

• **Subscriptions-related businesses** (c.35% revenue) performing well:
  - Resilient and predictable performance
  - Strong renewal rates and steady new business at **Informa Intelligence**, with particular strength in Pharma
  - Consistent performance at **Taylor & Francis**, underpinned by strong subscription renewals

• **Events-related businesses** (c.65% revenue) trading robust prior to emergence of the COVID-19 pandemic:
  - Solid start to the year at **Informa Markets**, with good performances by major brands in the US
  - Strong rebooking for Jan/Feb 2021 shows in **Healthcare** *(Arab Health +20%)*, **Advanced Manufacturing** *(MD&M West +8%)* and **Real Estate & Construction** *(Roofing Show +11%)*

• All Informa China offices re-opened and return to increasingly normal work patterns
  - Continuing bookings and cash collections as COVID restrictions ease;

• **COVID-19 Action Plan extended further**
  - Enhanced range of **Financing Control** and **Cost Management** Measures to provide **Stability & Strength** to the other side of the COVID-19 pandemic
  - Annualised direct/indirect cost savings increased to £130m+
Enhanced COVID-19 Action Plan

**MANAGEMENT ACTIONS**
- Fast and targeted action through launch of COVID-19 Action Plan in January
- Enhanced Cost Management Measures delivering **annualised direct/indirect savings of £130m+**
- Enhanced Financing Control Measures, including temporary Dividend suspension & US PP alignment

**POTENTIAL EQUITY ADDITION**
- Non pre-emptive placing of up to 19.99% of Informa’s existing share capital, **raising c.£1bn**
- Full participation from the entire **PLC Board** and international **Executive Management Team**
- Major shareholders consulted prior to release of announcement

**USE OF POTENTIAL PROCEEDS**
- Strengthens Informa’s balance sheet, reducing overall debt and lowering leverage
- Further enhances operating strength, taking **headroom on facilities up to £2.3bn+**
- Provides “Stability & Strength” to other side of COVID-19 pandemic

**CONSIDERED TIMING**
- COVID-19 Action Plan, preserving strength and building stability in first half of disruption in 2020
- Enhances and aligns with covenant waiver discussions
- Bridges temporary gap between revenue and costs, minimising long-term damage to business

**PRO-FORMA NET DEBT**
- Net Debt pre-equity placing of £2,356m; **Net Debt post-equity placing of £1,356m¹**
- No covenant on Bonds & RCF; US Private Placement notes at 3.5x net debt / EBITDA
- No material debt maturities until 2023

---

¹Net debt pre-IFRS 16 as at 31 December 2019. Post placing figure assumes £1bn raise, ex-fees

Informa: Stability & Strength
2020 COVID Outlook: The Operating Case & The Vigilant Case

The Operating Case assumes a phased and gradual return for our Events brands:

- Zero F2F Events revenue in Q2
- Phased resumption of F2F Events activity, with international participation lagging Domestic
- Zero revenue on 60+ Events already Cancelled
- 30-40% revenue attrition on 400+ Events rescheduled from H1 into H2 2020, to reflect softer demand due to change in dates, underlying market trends and upgraded bio-security measures
- 10%-20% revenue attrition on Events originally scheduled for H2 2020 that still take place
- Total Events-related revenue of c.£1bn in H2 with c75% in the last four months
- Group revenue broadly flat in Q1
- Subscriptions-related revenue steady

The Vigilant Case assumes a more prolonged return for our Events brands:

- Zero F2F Events revenue in Q2 and Q3
- Phased resumption of F2F Events activity, with international participation lagging Domestic
- Zero revenue on 2020 Events already Cancelled
- Zero revenue on an assumed 430+ additional Events cancelled in H2 under The Vigilant Case
- 30-40% revenue attrition on 400+ Events rescheduled from H1 into Q4 2020 to reflect softer demand due to change in dates, underlying market trends and upgraded bio-security measures
- 10%-20% revenue attrition on Events originally scheduled for Q4 2020 that still take place
- Group revenue broadly flat in Q1
- Subscriptions-related revenue steady

1 The Numbers on this and following pages relating to The Operating Case and The Vigilant Case are the result of modelled scenarios based on a number of underlying assumptions which have not been verified by any independent source for accuracy or completeness. By their nature, the model, methodology and consequently the numbers may not be correct or complete and therefore should not be treated as, or considered to be, a forecast.
COVID Operating Model: Vigilant Case Impact

Region (% of H2 Rev) | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
---|---|---|---|---|---|---|---|---|---|---
Mainland China (10%+) | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS
Hong Kong (<10%) | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS
Singapore (<5%) | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS
Rest of ASEAN (<5%) | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS
Middle East & Africa (<5%) | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS
Europe (20%+) | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS
North America (35%+) | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS
South America (<5%) | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS | NO EVENTS

2020 THE VIGILANT CASE (“Downside Case”)
- Zero events until October
- Total Revenue Reduction of £1bn+
- Total Cost Savings of £500m+
- Pure Events Revenue 2020 –60% vs 2019
- Pure Events Revenue Q2/Q3 –100% vs 2019

EQUITY PLACING SUPPORTING STABILITY & STRENGTH TO THE OTHER SIDE OF COVID-19
## COVID Operating Model: Vigilant Case Impact

<table>
<thead>
<tr>
<th></th>
<th>2019 Actual</th>
<th>Early Jan 2020 Consensus¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group Revenue</td>
<td>£2,890m</td>
<td>£2,915m</td>
</tr>
<tr>
<td>Pure Events Revenue²</td>
<td>£1,791m</td>
<td></td>
</tr>
<tr>
<td>Group Adjusted Operating Profit</td>
<td>£933m</td>
<td>£942m</td>
</tr>
<tr>
<td>Net Debt (pre-IFRS16)</td>
<td>£2,356m</td>
<td>£2,059m</td>
</tr>
<tr>
<td>Leverage</td>
<td>2.5x</td>
<td>c2.0x</td>
</tr>
</tbody>
</table>

### 2020 THE VIGILANT CASE (“Downside Case”)

- Events already cancelled: £150m+ Revenue reduction
- Further Events assumed to be cancelled: 430+ events / c£450m net Revenue reduction, post attrition
- H1 2020 Events Rescheduled to H2: £275m+ of Revenue
- 30-40% attrition on events rescheduled: 120+ Events / c£110m+ Revenue reduction
- 10%-20% attrition on original H2 Events that go ahead: £160m+ Revenue reduction
- Cost Savings across Directs & Indirects: £500m+

### Versus 2019 Reported

- Vigilant Case Pure Events Revenue 2020 -60%
- Vigilant Case Pure Events Revenue Q2/Q3 2020 -100%

### 2020 THE VIGILANT CASE

- Group Revenue: £1.5bn to £2.0bn
- Pure Events Revenue: £0.5bn to £1.0bn
- Leverage: 6.0x to 6.5x

¹Company compiled consensus from January 2020; ²Revenue from direct Events-related activities, excluding other revenue not attached to an event
Updated COVID-19 Action Plan: Targeted response

COVID-19 ACTION PLAN

Prioritise Colleagues, Brands, Customers & Markets

Strict adherence to Government and health authority guidance

1. Financing Control Measures
   - Liquidity post placing £2.3bn+

2. Cost Management Measures
   - Annualised Cost Savings £130m+

3. Operating Flexibility Measures
   - Postponed Revenue £460m+

4. Colleague Support Measures
   - Flexibility, Guidance & Support

Targeted Measures supporting near-term pressure created by COVID-19, protecting long-term strength and value

THE RIGHT DECISIONS FOR COLLEAGUES, BRANDS, CUSTOMERS & MARKETS
Financing Control Measures: Extended

COVID-19 ACTION PLAN

1. FINANCING CONTROL MEASURES

Temporary Dividend Suspension

- Withdrawal of 2019 Final Dividend
- 2020 Dividends to be reviewed later in the year
- Enhances covenant discussions and terms of waiver agreement

Covenant Waiver

- Constructive discussions with US PP holders
- Process expected to complete within 4-6 weeks
- Discussions enhanced by Temporary Dividend Suspension and Equity Issue

Liquidity Backstop

- Surplus Committed Credit Facility of £750m on top of £900m RCF (net c£260m drawn)
- Completed application for eligibility to access UK Government COVID Corporate Finance Facility
- Total liquidity of £2.3bn+ including potential equity placing
- Enhances covenant discussions and terms of waiver agreement

Equity Support

- Proposed c£1bn equity issue to provide Stability & Strength to other side of COVID-19
- Removing short-term decisions that damage the business
- Full participation from the entire PLC Board and international Executive Management Team
- Enhances covenant discussions and terms of waiver agreement

Total liquidity of £2.3bn+
1 Long-term balance sheet strength

Pro-forma debt maturity as at 31 Dec 2019 (£m)¹

<table>
<thead>
<tr>
<th>Year</th>
<th>USPP</th>
<th>EMTN bonds</th>
<th>Bank Facilities drawn</th>
<th>Bank Facilities undrawn</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020</td>
<td>100</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>2021</td>
<td>100</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>2022</td>
<td>100</td>
<td>200</td>
<td>300</td>
<td>0</td>
</tr>
<tr>
<td>2023</td>
<td>100</td>
<td>200</td>
<td>300</td>
<td>0</td>
</tr>
<tr>
<td>2024</td>
<td>100</td>
<td>200</td>
<td>300</td>
<td>0</td>
</tr>
<tr>
<td>2025</td>
<td>100</td>
<td>200</td>
<td>300</td>
<td>0</td>
</tr>
<tr>
<td>2026</td>
<td>100</td>
<td>200</td>
<td>300</td>
<td>0</td>
</tr>
<tr>
<td>2027</td>
<td>100</td>
<td>200</td>
<td>300</td>
<td>0</td>
</tr>
<tr>
<td>2028</td>
<td>100</td>
<td>200</td>
<td>300</td>
<td>0</td>
</tr>
</tbody>
</table>

No Maturities until 2022

Balanced mix of secure, long-term funding

Substantial liquidity & cash (£2.3bn+ headroom post placing)

No near-term debt maturities

Resilient Subscriptions cash flow

No covenants on Bonds and RCF

Point covenant risk on US PP debt (3.5x Net debt / EBITDA)

ROBUST BUSINESS MODEL WITH STRONG CASH CONVERSION AND FREE CASH GENERATION

¹ Proforma for: (1) RCF +1 Extension executed Jan 2020; (2) Dec 2020 USPP Prepayment executed Feb 2020; (3) Surplus Committed Credit Facility Mar 2020
# COVID Operating Model: Vigilant Case Impact

## 2020 VIGILANT CASE ASSUMES A FULL REDUCTION OF £1BN+ IN EVENTS REVENUE

<table>
<thead>
<tr>
<th></th>
<th>2019 Actual</th>
<th>Early Jan 2020 Consensus¹</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Group Revenue</strong></td>
<td>£2,890m</td>
<td>£2,915m</td>
</tr>
<tr>
<td><strong>Pure Events Revenue²</strong></td>
<td>£1,791m</td>
<td></td>
</tr>
<tr>
<td><strong>Group Adjusted Operating Profit</strong></td>
<td>£933m</td>
<td>£942m</td>
</tr>
<tr>
<td><strong>Net Debt (pre-IFRS16)</strong></td>
<td>£2,356m</td>
<td>£2,059m</td>
</tr>
<tr>
<td><strong>Leverage</strong></td>
<td>2.5x</td>
<td>c2.0x</td>
</tr>
</tbody>
</table>

### 2020 THE VIGILANT CASE ("Downside Case")
- Events already cancelled: £150m+ Revenue reduction
- Further Events assumed to be cancelled: 430+ events / c£450m net Revenue reduction, post attrition
- H1 2020 Events Rescheduled to H2: £275m+ of Revenue
- 30-40% attrition on events rescheduled: 120+ Events / £110m+ Revenue reduction
- 10-20% attrition on original H2 Events that go ahead: £160m+ Revenue reduction
- Cost Savings across Directs & Indirects: £500m+

### Versus 2019 Reported
- Vigilant Case Pure Events Revenue 2020 -60%
- Vigilant Case Pure Events Revenue Q2/Q3 2020 -100%

### 2020 THE VIGILANT CASE ("Downside Case")
- Group Revenue £1.5bn to £2.0bn
- Pure Events Revenue £0.5bn to £1.0bn
- Achievable Leverage Post-Placing Less than 3.5x

¹Company compiled consensus from January 2020; ²Revenue from direct Events-related activities, excluding other revenue not attached to an event.
Strength & Opportunities in a Post-COVID-19 World

**PENT-UP DEMAND**

- **Trade & Commerce:** Exhibitions provide a highly efficient platform for transactions and trade
- **Major brands:** The powerful shows are likely to become more powerful and prioritised, providing reach, efficiency and scale
- **Booking trend:** Customer commitments and rebooking rebound quickly as restrictions ease
- **Face-to-Face:** The power and value of face-to-face interaction at scale only more evident following absence
- **Incentives:** Venue and State support for rebound and recovery of exhibitions industry, helping stimulate trade in major destinations eg Hong Kong to subsidise venue costs for 12 months

**A POST-COVID EXHIBITIONS INDUSTRY**

- **Bio-Security:** Enhanced hygiene measures likely to become standard practise eg mobile data screening, on-site temperature checks, on-site quarantine, hand sanitation, deep cleaning protocols, electronic registration, enhanced waste management
- **Visa & Entry Management:** Additional controls and complexity likely for visas and permits
- **Digital strength:** Need for stronger fusion of physical and digital product to deliver greater value for Customers
- **Market Maker:** Ability to support and stimulate market growth and innovation becomes ever more valuable
- **Scale & Specialisation:** Ability to meet post-COVID industry reality through depth in specialist markets and proximity to customers

**LONG TERM ATTRACTION & VALUE OF INDUSTRIAL TRADE SHOWS, ENHANCED BY DIGITAL CAPABILITIES AND WORLD-CLASS BIO-SECURITY**
Pent-Up Demand & the Power of Major Tradeshow Brands

The postponement of Vitafoods Europe was amongst the most acute indicators that 2020 would unfold differently than planned. It’s been imperative to structure continuous business as best we can until normality returns later in the year—including the resumption of tradeshows where we conduct a good deal of our business.

Unfortunately there is no real replacement for the many nuances of true, in-person contact. Licensing Expo is the largest physical manifestation of the marketplace of ideas that IS the licensing business. As you all know, many of the best ideas and relationships are spawned by the casual conversation at a networking reception, on the Starbucks line, over dinner, across a meeting table where the slightest bit of body language can speak volumes more than a well-delivered email or phone pitch. Because of this, we eagerly await the chance to come together, collaborate and share at Expo late this summer.

We really miss the buzz that surrounds these exhibitions. It is an unusually long time for us not meeting with customers...
The virus has affected face to face communications globally and so it becomes even more important how tradeshows are needed to help businesses.

Informa: Stability & Strength

Preparations for Jewellery & Gem World Hong Kong in September – the biggest and most important marketplace of its kind in the world – have been in full swing for months – even shifting into higher gear during the last three weeks. As of today, we have sold nearly the same amount of exhibition space compared with the same period last year – and we are signing up new and returning exhibitors every day. This is a strong indication of just how driven our customers are in terms of capturing the massive amount of pent-up demand that has been deferred since February of this year.

Unfortunately there is no real replacement for the many nuances of true, in-person contact. Licensing Expo is the largest physical manifestation of the marketplace of ideas that IS the licensing business. As you all know, many of the best ideas and relationships are spawned by the casual conversation at a networking reception, on the Starbucks line, over dinner, across a meeting table where the slightest bit of body language can speak volumes more than a well-delivered email or phone pitch. Because of this, we eagerly await the chance to come together, collaborate and share at Expo late this summer.

The industry has warmly welcomed the postponement of China Beauty Expo to later in the year. As soon as the news came out, some leading exhibitors also expressed their wish to expand booth participation since they expect a strong rebound in China during the second half of the year.

Cash collections across all of Informa’s business in China are resuming, with total March collections 4x larger than February.
STABILITY & STRENGTH TO THE OTHER SIDE OF THE COVID-19 PANDEMIC

COVID-19 Market Disruption
- Temporary control measures
- Temporary travel restrictions
- Temporary restrictions on gatherings
- Temporary lockdown in US, UK and elsewhere
- Temporary deferral of Events revenues

COVID-19 Informa Action Plan
- Attractive, growing information markets
- International reach & balance (China/US)
- Portfolio of market-leading Brands
- No 1 B2B Trade Show Group globally
- High quality, recurring digital subscriptions revenues (Advanced Learning/Pharma & Finance)
- Highly cash generative

- Lean into strength of subscriptions-related businesses (35% of revenue)
- Cost Management Measures: £130m+ annualised savings to date
- Financing Control Measures: £2.3bn+ headroom\(^1\), dividend suspension
- Operating Flexibility Measures: Postponement Programme
- Colleague Support Measures

\(^1\)Headroom calculation assumes c£640m headroom in RCF, £750m Surplus Credit Facility and a £1bn placing
2. COST MANAGEMENT MEASURES

Recruitment Pause
- Postponement of all recruitment
- Limited exceptions for direct revenue generators
- Review of all contractors / consultants

Rewards Phasing
- Postponement of salary/merit/cost of living reviews
- Voluntary Leadership Salary Sacrifice:
  - CEO and CFO at 33%
  - Board at 25%, with remaining fees in equity
  - Executive Team at 25%

Project Review
- Postponement of all non-essential projects
- Cash retention in the business
- Back-end phasing of exceptional Capex

Discretionary Costs
- Remove all non-essential discretionary spend
- Travel minimisation
- Professional fees, consultants and advisor costs

Employment Flexibility
- Unpaid leave through Informa 2020 Sabbatical
- Accelerated use of vacation time
- Expanded volunteering opportunities

VIGILANT COST MANAGEMENT PRESERVING UNDERLYING STRENGTH & VALUE OF BUSINESS

*Annualised indirect cost savings from Cost Management Measures announced by 06/04/20 and direct savings from events already cancelled
3 Operating Flexibility Measures: Extended

The Postponement Programme: Further extended since 10 March

**100+** Brands run successfully in 2020 so far *(100+ Brands on 10/3)*

**60+** Large Brands agreed or in process of rescheduling in 2020 – revenue £340m+ *(c45 Brands on 10/3)*

**340+** Smaller Brands agreed or in process of rescheduling in 2020 – revenue £120m+ *(c70 Brands on 10/3)*

**60+** Brands Re-Phased to 2021 or Cancelled – revenue c.£150m+ *(13 Brands on 10/3)*

Localisation and Virtualisation where the best solution for customers in 2020

Investment in venues, marketing, customer support and other duplicative costs

In-market support budgets and insurance outcomes

Investment in developing industry standard bio-security protocols and controls

**COVID-19 ACTION PLAN**

**3. OPERATING FLEXIBILITY MEASURES**

*Postponed and Cancelled revenues reflect those Events announced by 06/04/20*
**Colleague Support Measures: Extended**

**COVID-19 ACTION PLAN**

**4. COLLEAGUE SUPPORT MEASURES**

- **In-Market Support**
  - Strict adherence to local government and health authority advice
  - Re-opening guidance, with strict adherence to bio-security measures

- **Remote Working Capability**
  - Seamless move to remote working across the Group
  - Full 24/7 Tech support

- **Digital & Virtualisation**
  - Effective platforms for close customer engagement
  - Virtual events and digital *Stay Connected* content

- **Regular Communications**
  - Weekly CEO update (video and virtual)
  - Weekly Group-wide Town Halls with CEO
  - Weekly Divisional Leadership updates

- **Volunteering Flex**
  - Volunteering policy relaxed to facilitate in-community and family support

- **Colleague Support Fund**
  - Discrete fund created to support Colleagues in particular financial hardship due to COVID-19

**SUPPORTING & NURTUREING OUR CORE STRENGTH, THE KNOWLEDGE & EXPERTISE WITHIN OUR BUSINESS**
Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. Through more than 450 international B2B brands, we provide opportunities to engage, experience and do business via face-to-face exhibitions, specialist digital content and actionable data solutions.

- **Revenue by type**
  - 2019
  - Exhibitor
  - Marketing Services
  - Sponsorship
  - Attendee
  - Other

- **Revenue by vertical**
  - 2019
  - Healthcare & Pharma
  - Health & Nutrition
  - Infrastructure, Construction & Build.
  - Fashion & Apparel
  - Maritime, Transport & Logistics
  - Manufacturing, Machinery & Equip.
  - Beauty & Aesthetics
  - Jewellery
  - Hospitality, Food & Beverage
  - Aviation
  - Other

- **Revenue by region**
  - 2019
  - North America
  - Cont. Europe
  - UK
  - Asia
  - Middle East
  - Rest of World

- **Key Figures**
  - **£1.5bn** Revenue
  - **£0.5bn** Adj. Op Profit
  - **450+** B2B Brands
  - **5,000+** Colleagues
  - **5.8m+** Attendees
  - **4.6m sqm+** Exhibition Space
  - **4.3%+** Underlying Growth
  - **50%** Group Revenue

Informa: Stability & Strength
Informa Connect is the Group's Content, Connectivity and Data business, organising content-driven events, training and programmes that provide a platform for professional communities to meet, network and share knowledge. With over 800 events each year in over 60 countries, it has particular strength in Life Sciences and Finance.

- **Revenue**: £275m+
- **Adj. Op Profit**: £45m+
- **£1m+ Brands**: 45+
- **Underlying Growth**: c.3%
- **Group Revenue**: 1,200+
- **Delegates**: 700k+
- **YoY digital audience**: +27%

**Revenue by type**
- Attendee
- Sponsorship
- Exhibitor
- Marketing Services

**Revenue by vertical**
- Healthcare & Pharma
- Finance
- Leisure
- Property
- Industrial
- Tax, Law & Accounting
- Other

**Revenue by region**
- North America
- Cont. Europe
- UK
- Asia
- Middle East
- Rest of World

Informa: Stability & Strength
Informa Intelligence provides specialist data, intelligence and insight to businesses, helping them make better decisions, gain competitive advantage and enhance return on investment. Through a range of specialist B2B subscription brands, we provide critical intelligence to niche communities within Pharma, Finance and Transportation.
Informa Tech informs, educates and connects specialist Technology communities around the world. Through more than 100 B2B brands, we provide specialist intelligence and knowledge, and build platforms for customers to engage, learn and be inspired to create a better digital world.

**Informa Tech Today**

- **£250m+** Revenue
- **£70m+** Adj. Op Profit
- **100+** B2B Brands
- **3.8m** Monthly Readers
- **1000+** Colleagues
- **600+** Subject Experts

**Revenue by type**
- 2019: Attendee, Exhibitor, Subscription, Sponsorship, Marketing Services

**Revenue by tech sub-vertical**
- 2019: Enterprise IT, Security, Service Providers, Gaming, Media & Entertainment, AI, Other

**Revenue by region**
- 2019: North America, Cont. Europe, UK, Asia, Middle East, Rest of World

Informa: Stability & Strength
Taylor & Francis Today

Taylor & Francis publishes peer-reviewed scholarly research and specialist reference-led academic content across subject areas within Humanities & Social Sciences and Science, Technology and Medicine. It is recognised internationally through its major publishing brands such as Taylor & Francis, Routledge, CRC Press and Dove Medical Press.
Thank you